Kornimate/medical-research-clean huggingface dataset:
calcium and gut hormones

Conditions: Obesity; Diabetes

Summary: gut hormones have therapeutic potential in the prevention and treatment obesity and type 2 diabetes (t2d). rodent evidence suggests that calcium may stimulate gut hormone secretion. evidence in humans however, is lacking. this study aims to assess whether the calcium ingestion stimulates gut hormone availability in humans.


Eligibility criteria:
inclusion criteria: * healthy men and women age between 18-65 yrs. * able to consume provided supplement. * weight stable for the past 3 month (no change within 3%) exclusion criteria: * any previous or current metabolic, cardio-pulmonary or musculoskeletal disease * not between the ages of 18-65 years * a body mass index below 18.5 kg/m2 or above 30 kg/m2 (body mass (kg) divided by your height (m) squared) * taking medications that may influence your metabolism * plans to change your lifestyle (diet and/or physical activity) during the study period * not willing to refrain from alcohol containing drinks or unaccustomed exercise one day before the laboratory sessions. * current smoker
the impact of aortic valve compression during cardio-pulmonary resuscitation on patients with out-of-hospital cardiac arrest

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: purpose: this study aims to find out if the current way of performing chest compressions during resuscitation for patients who have suffered a cardiac arrest outside of the hospital is affecting their chances of recovery. recent research suggests that more than half of these patients receive chest compressions near their aortic valve, which might block blood flow and make their condition worse. we will use a special imaging technique called transesophageal echocardiography (tee) during resuscitation to see if compressions near the aortic valve impact patient outcomes. methods: we will conduct a study with patients who have suffered a cardiac arrest outside of the hospital and are receiving tee during resuscitation in the emergency department. some patients will not be included in the study, such as those who recover quickly before the tee is done, those who need other treatments before they recover, those with an unclear compression site, or those with poor or missing tee images. we will divide the patients into two groups: those with compressions near their aortic valve and those without. we will collect information on the patients, the tee recordings, the resuscitation process, and important time points. we will mainly look at whether the patients recover and maintain a steady heartbeat. we will also examine other factors like their carbon dioxide levels, whether they recover at all, if they survive to be admitted to the hospital, if they survive to be discharged, and if they have good brain function when they leave the hospital. we plan to have 37 patients in each group for accurate results.


Eligibility criteria:
inclusion criteria: * patients aged 20 or older who arrived at the ed with non-traumatic ohca and underwent tee during resuscitation exclusion criteria: 1. early rosc before obtaining tee image; 2. insert the reboa before rosc; 3. initiate ecmo flow before rosc; 4. cannot identify compression site on tee; 5. poor quality of tee image; 6. missing tee image.
functional mri of stress in obesity

Conditions: Obesity

Summary: to examine the influence of obesity on brain activation during food cue, stress, and neutral relaxing conditions

subjects will participate in an fmri session to examine changes in frontal and limbic brain regions with food cues, stress and neutral/relaxing imagery

Eligibility criteria:
inclusion criteria: 1. between ages 18-50 years old. 2. able to read and write. 3. negative urine toxicology screens during intake appointments indicating no history of current or past dependence on alcohol or illicit drug use. 4. women: have a regular menstrual cycle. 5. bmi: 30 \< bmi \< 35 for obese subjects (upper limit of 35 selected given our experience with heavier individuals fitting comfortably in the fmri scanner) and 18.5 \< bmi \<25 for normal weight subjects (institute, 2006) exclusion criteria: 1. any major neurological illness or injury and any current or prior clinically significant mental health (including ptsd) or substance use disorder (with exception of nicotine dependence) as determined by scid interview; 2. regular use of any psychoactive drugs including anxiolytics and antidepressants. 3. any significant current medical condition such as neurological, cardiovascular, endocrine, renal, liver, thyroid pathology; subjects on medications for any medical condition will be excluded. 4. any subjects with foreign ferromagnetic metal objects in their body or other mr contraindications will be excluded including subjects who work as welders. 5. women on oral contraceptives, peri- and post-menopausal women, and pregnant or lactating women (as alterations in stress response are associated with these states).
assessment of mri in patients with implanted cardiac devices

Conditions: Arrhythmias, Cardiac

Summary: the research goal is to continue to add to the extensive body of peer-reviewed evidence that demonstrates mri may be safely performed in patients with cieds, after they have been evaluated and cleared by cardiology. this study will allow the researchers to collect data from the facilities ongoing clinical practice regarding the number and types of any adverse clinical reactions, and also to document any changes in the implanted cardiac device that may have occurred during the mri scan. the researchers will also be assessing the results of the mri and how the imaging findings impact patient care and the clinical outcome of the patient. this data will then be presented to the fda and the centers for medicare and medicaid services to further influence federal guidelines and payment structures.

cardiac implantable electronic devices (cieds) generally refer to implanted pacemakers and defibrillators for patients with cardiac disorders affecting their heart rhythm. previously, cieds have been regarded as a contraindication to magnetic resonance imaging (mri) scans, with concerns that the magnetic fields of the mri may cause problems with the patient's cied. however, this is a major healthcare issue, as approximately 50-75% of patients with implanted cieds are expected to need a future mri as part of their clinical care. the inability to get such a test may negatively impact the ability to diagnose and treat future diseases. however, many of the initial concerns regarding the capability of performing mri in patients with cied have likely been overstated. there is peer-reviewed literature dating back to the 1990s regarding the ability to safely perform mri in patients with cieds, if certain protocols are followed regarding patient selection and monitoring. in 2011, nazarian et al from johns hopkins university published a study on 438 patients with cied that received mri. there were no adverse clinical effects from this study. in fact, the american college of radiology updated it's guidance document for safe mr practices, and cieds are no longer listed as a relative contraindication to obtaining an mri. however, the presence of cieds are still regarded as a relative contraindication to performing mri at some centers. in addition, performance of mri in the setting of cied is denied by the centers for medicare and medicaid services. continued accrual of data regarding the safety of performing mri in patients with cieds is needed, including outcomes studies that document the clinical impact of improved diagnostics provided by the mri on patient care.

Eligibility criteria:
inclusion criteria: * all patients that require an mri as part of the normal course of their medical care that also have a cied and are candidates for mri . exclusion criteria: * patient does not require an mri for their medical care * patient does not have a cied * patient has not been seen or approved by cardiology to be a candidate for mri * patients under the age of 18 * pregnant patients * prisoners
tolerability and efficacy of am and pm once daily dosing with extended-release guanfacine hydrochloride in children 6-12 with attention-deficit/hyperactivity disorder (adhd) (the adhd tempo study)

Conditions: Attention-Deficit/Hyperactivity Disorder

Summary: the primary purpose is to assess the efficacy of once daily dosing with optimized spd503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with adhd as measured by change from baseline score at endpoint on the adhd-rs-iv.


Eligibility criteria:
inclusion criteria: * 6-12 years old * adhd diagnosis * adhd-rs-iv minimum score of 28 * cgi-s score \> or = 4 exclusion criteria: * current, controlled or uncontrolled, comorbid psychiatric diagnosis * condition or illness which represent inappropriate risk to subject * known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems, exercise-related cardiac events, or clinically significant bradycardia; orthostatic hypotension or controlled or uncontrolled hypertension * use of prohibited medication that have cns effects or affect cognitive performance * history of alcohol or substance abuse within 6 months * current use of medication that affect bp or heart rate * significantly overweight * weight of less than 55 lbs * known allergy to spd503 * abnormal urine drug and alcohol screen

Keywords: adhd
assessment of intracardiac electrograms transmitted by home monitoring for the remote follow-up of pacemaker (prems)

Conditions: Bradycardia

Summary: the purpose of the prems study is to evaluate the capability of the periodic iegm feature (intracardiac electrogram) to provide more extensive remote information about cardiac rhythm, sensing and capture, and thus to detect anomalies that may deserve a clinical action. prems is a non-interventional, prospective, and multicenter study. the primary objective is to assess the added clinical value of periodic iegms, based on the rate of patients with a rhythm or sensing/pacing anomaly detected on the first iegm transmitted by home monitoring (hm) and non detectable so obvious on the other parameter set offered for the remote follow-up.


Eligibility criteria:
inclusion criteria: * patient implanted with a single or dual chamber pm within the last 3 months * home-monitoring activated and functional * periodic iegm "on" and programmed at 30 days intervals * patient willing and able to comply with the protocol and who has provided written informed consent about hm * patient whose medical situation is stable exclusion criteria: * age \< 18 years * patient unable to handle the cardio messenger correctly * participation in another clinical study

Keywords: pacemaker remote monitoring remote follow-up home monitoring periodic iegm intracardiac electrogram
a safety study of ly2811376 single doses in healthy subjects

Conditions: Alzheimer's Disease

Summary: this is a phase 1 study in healthy subjects to evaluate the safety and tolerability of ly2811376 single doses, how the body handles the drug, and the drug's effect on the body.

this is a phase 1 study with 2 parts, both in healthy subjects. part 1 is a subject- and investigator-blind, placebo-controlled, randomized, 3 period, crossover study. part 1 will assess the safety and tolerability of ly2811376 single doses, how the body handles the drug, and the drug's effect on the body. part 2 is a subject- and investigator-blind, placebo-controlled, randomized study to assess the safety and tolerability of a ly2811376 single dose, how the body handles the drug, and the drug's effect on the body including in cerebrospinal fluid.

Eligibility criteria:
inclusion criteria: * healthy men and nonchild-bearing potential women * 20 years or older * body mass index between 18-32kg/m2 exclusion criteria: * taking over-the-counter or prescription medication with the exception of vitamins or minerals or stable doses of thyroid or estrogen hormone replacement. * smoke more than 10 cigarettes per day. * consume more than 5 cups of coffee per day.
a phase 1b, single center, clinical study to investigate the safety and biological responses to baminercept in patients with chronic hcv hepatitis.

Conditions: Chronic HCV Hepatitis C

Summary: erstes safety trial mit baminercept in chronischen hcv patienten. untersuchung des potentiell antiviralen, antiinflammatorischen effekts sowie modulation der hepatischen gen-expression. 10 patienten, open label, 10 wochen therapie. sequentielles enrollement der ersten 4 patienten. * trial with medicinal product


Eligibility criteria:
inclusion criteria: informed consent age 18-60 years chronic hcv infection non responder (to peg-ifn alpha2/ribavirin containing therapy) elevated alt liver biopsy at screening without sings of (pre-)cirrhosis compensated liver function absolute neutrophil count \> 1500 / mm3 at screening hemoglobin \> 10 g/dl at screening calculated creatinine clearance of \> 60 cc/min at screening normal tsh at screening exclusion criteria: hbv infection evidence for concomitant liver disease other than hcv hepatitis evidence for a hcc alpha-fetoprotein \>20ng/ml autoimmune disease ana \> 1/320, documented in the last 6 months hiv 1/2 infection alt and ast \>3x uln, alkaline phosphatase \>2,5x uln known hypersensitivity or allergy to baminercept other clinically significant concomitant disease states known or suspected non-compliance to study protocol, drug or alcohol abuse infections other than hcv hepatitis clinically important chest x-ray abnormality at screening body mass index (bmi) \> 30kg/m2 concomitant systemic immunosuppressive/-modulating therapy treatment with anticoagulants receipt of live vaccine within 4 weeks prior to study start symptomatic hypogammaglobulinemia with history of recurrent infections subjects with a history of malignant disease treatment with other investigational products or participation in an interventional clinical trial within the last 3 months pregnancy or breastfeeding inability or refusal to practice a safe contraception
postpartum pelvic floor workshop

Conditions: Pelvic Floor Disorders; Pelvic Floor; Incompetency; Pelvic Floor Muscle Weakness; Perineum; Injury

Summary: after having a baby, there are some expected changes in pelvic floor function. however, tearing of the pelvic floor, having a large baby and needing a vacuum or forceps to deliver the baby put women at risk for having pelvic floor disorders. our study aims to see if, in women who had a high risk for pelvic floor disorders, a pelvic floor education workshop four weeks after delivery can improve pelvic floor disorders compared to those that did not have a workshop.

there is compelling evidence for the need for perineal education and care, especially in women who have recognized risk factors. for example, 30-50% of women who have a clinically recognized risk factor report anal incontinence, fecal urgency, dyspareunia and perineal pain. despite this, a study found that less than 50% of women with anal incontinence voice those symptoms unless directly asked about them. some authors discuss how women may not share these symptoms with their care providers out of the belief that it is a "normal" effect of childbirth. a review of the literature shows that antenatal educational workshops can be an effective means to provide pregnant women with information regarding pelvic floor health, including how modes of delivery impact pelvic floor function. similarly, antenatal pelvic floor workshops have been found to improve patients' knowledge on pelvic floor health, their practice of pelvic floor muscle exercises and their confidence with these exercises. to our knowledge, there is no literature exploring the role of a postpartum pelvic floor workshop, on managing perineal and pelvic floor symptoms in women who are identified as being at higher risk of developing pelvic floor dysfunction. our goal is to develop and assess such a workshop.

Eligibility criteria:
inclusion criteria: * postpartum (ie no more than 4 weeks postpartum at time of group allocation) * vaginal delivery * sustained one or more of the following insults to perineum/pelvic floor * third or fourth degree laceration * vacuum or forceps assisted vaginal delivery * delivery of macrosomic infant ≥4000g) exclusion criteria: * prior pelvic floor physiotherapy treatment * prior surgical management for pelvic organ prolapse or incontinence * unable to understand english * caesarean delivery * concerns for patient sensitivity - eg if team is aware of neonatal demise, neonate unwell in nicu etc

Keywords: postpartum perineal education
bioinformation therapy for pancreatic cancer

Conditions: Unresectable Pancreatic Cancer

Summary: the aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable pancreatic cancer.

by enrolling patients with unresectable pancreatic cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. the efficacy will be evaluated according to local relief degree, progress free survival (pfs) and overall survival (os).

Eligibility criteria:
inclusion criteria: * all standard therapies have failed according to nccn guidelines or the patient refuses standard therapies * body tumor 1-6, with at least one tumor length \> 2 cm * kps ≥ 70, lifespan \> 6 months * platelet count ≥ 80×109/l，white blood cell count ≥ 3×109/l, neutrophil count ≥ 2×109/l, hemoglobin ≥ 80 g/l exclusion criteria: * patients with cardiac pacemaker * patients with brain metastasis * patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Keywords: cancer ablation life information rehabilitation therapy
small stitch study

Conditions: Anterior Vaginal Wall Prolapse

Summary: a descent of the anterior vaginal wall is the most common form of female pelvic organ prolapse (pop). although anterior colporrhaphy (ac) is accepted worldwide as a "standard procedure", its exact steps are not well standardized. we developed a small stitch anterior colporrhaphy (sstac) in an effort to increase the strength and durability of ac objectives the aim of this pilot study is to demonstrate the feasibility and complication rate of the sstac and to assess the anatomical and functional outcomes after this method of cystocele repair.

a prospective case series evaluation of sstac following the recommendations of ideal-collaboration (www.ideal-collaboration.net) will be performed. the newly developed procedure will be tested in a group of 10 patients, who equals stage 2a in the development and innovation of surgical innovations. in this stage safety and technical success is the main outcome. as technical modifications may be common during stage 2a and their nature and timing should be meticulously recorded, the videotaping during all surgical procedures will be performed.

Eligibility criteria:
inclusion criteria: * women older than 18 years of age * able to read, understand and sign informed consent * symptomatic cystocele described as points aa or ba \>= 0 according to the international continence society pelvic organ prolapse quantification system (pop-q) exclusion criteria: * previous urogynecological operation * gynecologic malignancy * planned concomitant incontinence operation * other contraindications for surgery * pregnancy * systemic glucocorticoid treatment * contraindication for the surgery

Keywords: prolapse anterior colporrhaphy
effects of rtms on respiratory function and gut microbiota in patients with brain injury

Conditions: Brain Injuries; Respiratory Function Impaired; Gut Microbiota

Summary: impaired respiratory function may occur after brain injury, and will progress to restricted respiratory dysfunction without early intervention. at present, there is a lack of effective treatment options for respiratory dysfunction. repetitive transcranial magnetic stimulation(rtms) is a non-invasive, painless and non-invasive neuroregulatory technique. in healthy people, rtms applied to the respiratory motor cortex induces a contralateral respiratory muscle response. however, whether rtms can improve respiratory function in patients with brain injury remains unclear. gut microbiota can affect muscle function and mass, and animal experiments have shown that probiotics can increase skeletal muscle mass and grip strength in mice. on the other hand, studies have found that rtms can improve the nutritional status of patients with vegetative state by regulating the structure of gut microbiota. however, it remains unclear whether rtms can improve respiratory muscle function in patients with brain injury by regulating gut microbiota. therefore, the investigators intend to apply rtms to the respiratory motor cortex to observe whether rtms can improve respiratory function and reduce the incidence of pneumonia in patients with brain injury, and to observe the role of gut microbiota in this process.


Eligibility criteria:
inclusion criteria: * in line with the diagnostic criteria of "chinese classification of cerebrovascular diseases(2015)" mrs score 2-4 points or craniocerebral injury caused by trauma, gcs score \> 8 points * between 18 and 70 years old * the first incidence of cerebrovascular disease or traumatic brain injury, and the course of disease was 10-180 days * vital signs are stable, no progression * voluntary participation with informed consent exclusion criteria: * patients with a history of respiratory disease, including chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, and lung cancer * severe bone malformations in the chest or spine * have other neurological or neuromuscular disorders * history of thoracic and abdominal surgery * severe heart, lung, kidney, liver or other organ dysfunction * pregnant and lactating women * epilepsy * metal implant * patients who were judged by the investigator to be unsuitable for participation in this trial